Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Asciminib in chronic myeloid leukemia: Superior efficacy and favorable safety outcomes from a systematic review and meta-analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

ASAhmet Sarıcı

Discussion

Loading...

Member takes

Overview

Systematic review and meta-analysis finds asciminib enhances efficacy and reduces adverse events compared to tyrosine kinase inhibitors in chronic myeloid leukemia.

Key Points

  • This research evaluates the efficacy and safety of asciminib in chronic myeloid leukemia patients.
  • Conducted a systematic review and meta-analysis of RCTs
  • Included patients with chronic-phase CML, both newly diagnosed and previously treated
  • Compared asciminib with control groups examining major molecular response and adverse events
  • Asciminib significantly improved major molecular response rates compared to controls (MD 1.45)
  • Demonstrated reduced risk of grade ≥3 adverse events compared to second-generation TKIs
  • Lower incidence noted for anemia and diarrhea among patients treated with asciminib

Cite This Study

Ahmet Sarıcı (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfd1https://doi.org/10.1182/blood-2025-7298
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review2026
  2. 2Asciminib as initial therapy with addition of lower dose tyrosine kinase inhibitors (TKIs) for patients with chronic myeloid leukemia who do not achieve optimal response or a deep molecular remission2025
  3. 3Clinical efficacy and safety of asciminib in chronic myeloid leukemia-chronic phase (CML-CP) in real-world settings: a systematic literature review2026
  4. 4Phase II trial of asciminib for newly diagnosed chronic myeloid leukemia.2026
  5. 5Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results2024 · 55 citations